F



F





Fertility agents


Infertility is defined as unsuccessful conception after 12 months of attempting to conceive, as opposed to sterility, the inability to reproduce. Infertility may be due to reproduction dysfunction of the male, female, or both.


Female infertility can be due to disruption of any phase of the reproductive process. The most critical phases include follicular maturation, ovulation, transport of the ovum through the fallopian tubes, fertilization of the ovum, nidation, and growth/development of the conceptus. Causes of infertility include the following:



Male infertility is due to decreased density or motility of sperm or semen of abnormal volume or quality. The most obvious manifestation of male infertility is impotence (inability to achieve erection). Whereas in female infertility an identifiable endocrine disorder can be found, most cases of male infertility are not associated with an identifiable endocrine disorder.



Action


Antiestrogens: Nonsteroidal estrogen antagonist that increases follicle-stimulating hormone (FSH) and leutinizing hormone (LH) levels by blocking estrogen-negative feedback at the hypothalamus.


Gonadotropins: Produce ovulation induction in women with hypogonadotropic hypogonadism and polycystic ovary syndrome (PCOS). Ovaries must be able to respond normally to FSH and LH stimulation.


Gonadotropin-releasing hormone (GnRH) agonists: Causes down-regulation of endogenous FSH and LH levels. GnRH agonists stimulate release of pituitary gonadotropins. Suppression of endogenous LH can decrease number of oocytes released prematurely, improve oocyte quality, and increase pregnancy rates.


Gonadotropin-releasing hormone (GnRH) antagonists: Suppresses endogenous LH surges during ovarian stimulation. GnRH antagonists avoid initial flare-up seen with GnRH agonists, shortening the number of days needed for LH suppression and allowing ovarian stimulation to begin within the spontaneous cycle.



Medications to induce ovulation








































































Name Category Availability Uses Side Effects
Cetrorelix (Cetrotide) GnRH antagonist I: 0.25 mg, 3 mg Inhibition of premature LH surges in women undergoing ovarian hyperstimulation OHSS (ovarian hyperstimulation syndrome): Abdominal pain, indigestion, bloating, decreased urinary output, nausea, vomiting, diarrhea, rapid weight gain, dyspnea, peripheral/dependent edema; headaches, pain/redness at injection site, mood swings, hot flashes, insomnia, vaginal dryness
Chorionic gonadotropin (Novarel, Ovidrel, Pregnyl) Gonadotropin I: 5,000 units, 10,000 units, 20,000 units
Ovidrel: 250 mcg/0.5 ml
In conjunction with clomiphene, human menotropins or urofolitropin to stimulate ovulation OHSS (ovarian hyperstimulation syndrome): Abdominal pain, indigestion, bloating, decreased urinary output, nausea, vomiting, diarrhea, rapid weight gain, dyspnea, peripheral/dependent edema; ovarian enlargement, ovarian cyst formation, headache, pain at injection site
Clomiphene (Clomid, Milophene, Serophene) Antiestrogen T: 50 mg Anovulation, oligo-ovulation with intact pituitary/ovarian response and endogenous estrogen Ovarian cyst formation, ovarian enlargement, visual disturbances, premenstrual syndrome, hot flashes, headaches, blurred vision, nausea, breast tenderness
Follitropin alpha (Gonal-F) Gonadotropin Injection, powder: 75 units, 450 units, 1,050 units
Injection, solution: 300 units/0.5 ml, 450 units/0.75 ml, 900 units/15 ml
In conjunction with human chorionic gonadotropin to stimulate ovarian follicular development in pts with ovulatory dysfunction not due to primary ovarian failure (e.g., anovulation, oligo-ovulation) OHSS (ovarian hyperstimulation syndrome): Abdominal pain, indigestion, bloating, decreased urinary output, nausea, vomiting, diarrhea, rapid weight gain, dyspnea, peripheral/dependent edema; flu-like symptoms, upper respiratory tract infections, bleeding between menstrual periods, nausea, ovarian enlargement, ovarian cysts, acne, breast pain/tenderness, mood swings
Follitropin beta (Follistim AQ) Gonadotropin I: 75, 350, 650, 975 international units FSH In conjunction with human chorionic gonadotropin to stimulate ovarian follicular development in patients with ovulatory dysfunction not due to primary ovarian failure (e.g., anovulation, oligo-ovulation) OHSS (ovarian hyperstimulation syndrome): Abdominal pain, indigestion, bloating, decreased urinary output, nausea, vomiting, diarrhea, rapid weight gain, shortness of breath, peripheral/dependent edema; flu-like symptoms, breast tenderness, dry skin, rash, dizziness, fever, headaches, nausea, fatigue, mood swings
Goserelin (p. 558) (Zoladex) GnRH agonist Implant: 3.6 mg, 10.8 mg Endometriosis, adjunct to menotropins for ovulation induction Hot flashes, amenorrhea, blurred vision, edema, headaches, nausea, vomiting, breast tenderness, weight gain, mood swings, insomnia, vaginal dryness
Leuprolide (p. 684) (Eligard, Lupron) GnRH agonist Injection, Solution: 5 mg/ml for subcutaneous injection
Injection, powder: 3.75 mg, 7.5 mg, 11.25 mg, 15 mg, 22.5 mg, 30 mg
Endometriosis, adjunct to menotropins/human chorionic gonadotropin for ovulation induction Hot flashes, amenorrhea, blurred vision, edema, headaches, nausea, vomiting, breast tenderness, weight gain, mood swings, insomnia, vaginal dryness
Menotropins (Menopur, Repronex) Gonadotropin 75 units FSH, 75 units LH activity In conjunction with chorionic gonadotropin for ovulation stimulation in pts with ovulatory dysfunction due to primary ovarian failure OHSS (ovarian hyperstimulation syndrome): Abdominal pain, indigestion, bloating, decreased urinary output, nausea, vomiting, diarrhea, rapid weight gain, dyspnea, edema of lower extremities; ovarian enlargement, ovarian cyst formation, breast tenderness, mood swings
Nafarelin (Synarel) GnRH 2 mg/ml nasal spray (200 mcg/spray) Endometriosis, adjunct to menotropins/human chorionic gonadotropin for ovulation induction Loss of bone mineral density, breast enlargement, bleeding between regular menstrual periods, acne, mood swings, seborrhea, hot flashes, headache, insomnia, vaginal dryness
Urofollitropin (Bravelle) Gonadotropin 75 units FSH activity In conjunction with human chorionic gonadotropin for ovulation stimulation in pts with polycystic ovary syndrome who have elevated LH:FSH ratio and have failed clomiphene therapy OHSS (ovarian hyperstimulation syndrome): Abdominal pain, indigestion, bloating, decreased urinary output, nausea, vomiting, diarrhea, rapid weight gain, shortness of breath, edema of lower extremities; ovarian enlargement, ovarian cyst formation, pain/redness at injection site, breast tenderness, nausea, vomiting, diarrhea, mood swings

Stay updated, free articles. Join our Telegram channel

Mar 8, 2017 | Posted by in NURSING | Comments Off on F

Full access? Get Clinical Tree

Get Clinical Tree app for offline access